Evidence map›Paper›PMID 39127850›Full record

ArticleScientific reports2024

Class A1 scavenger receptor antibody improves murine colitis by influencing macrophage and gut microbiota.

Jingling Su, Lupeng Liu, Yandan Ren, Yutong Gan, Yumei Lin, Chenxi Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingling SuDepartment of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201-209, Hubinnan Road, Siming District, Xiamen, 361004, Fujian Province, China.
Lupeng LiuDepartment of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201-209, Hubinnan Road, Siming District, Xiamen, 361004, Fujian Province, China.
Yandan RenDepartment of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201-209, Hubinnan Road, Siming District, Xiamen, 361004, Fujian Province, China.
Yutong GanDepartment of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201-209, Hubinnan Road, Siming District, Xiamen, 361004, Fujian Province, China.
Yumei LinDepartment of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201-209, Hubinnan Road, Siming District, Xiamen, 361004, Fujian Province, China.
Chenxi XieDepartment of Gastroenterology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, No.201-209, Hubinnan Road, Siming District, Xiamen, 361004, Fujian Province, China. fjzzxcx@163.com.

Funding

Natural Science Foundation of Fujian Province of China 2020J011205Natural Science Foundation of Fujian Province of China 2021J011323Xiamen Guidance Programs of Medicine and Health 3502Z20214ZD1054
6 · The paper itself

Abstract

This study aimed to investigate whether class A1 scavenger receptor (SR-A1) regulated macrophage polarization and gut microbial alteration during intestinal inflammation of colitis. A murine colitis model was established by feeding with dextran sulfate sodium (DSS), and treatment groups were injected intravenously with SR-A1 antibody. Results showed a preventive effect on colitis symptoms and fewer inflammatory cell infiltrates in treatment groups. Down-regulation of inflammatory cytokines and up-regulation of anti-inflammatory cytokine related to macrophages were seen in murine PBMC and LPMC after injected with SR-A1 antibody. The percentage of M2 macrophages was also elevated in treatment groups. In addition, SR-A1 antibody treatment resulted in the decreased apoptosis and increased proliferation of colonic epithelial cells. Other findings indicated that SR-A1 antibody injection could mediate its anti-inflammatory effect via inhibiting TLR4-MyD88-NF-kB signaling pathway and alterating the gut microbiota composition. Our research identified SR-A1 as a potential therapeutic target in inflammatory bowel disease (IBD).

Indexed as

ColitisGastrointestinal MicrobiomeMacrophagesScavenger Receptors, Class AAnimalsAntibodiesApoptosisCytokinesDextran SulfateDisease Models, AnimalMaleMiceMice, Inbred C57BLMyeloid Differentiation Factor 88NF-kappa BSignal TransductionAntibodiesCytokinesDextran SulfateMsr1 protein, mouseMyeloid Differentiation Factor 88NF-kappa BScavenger Receptors, Class ATlr4 protein, mouseToll-Like Receptor 4Class A1 scavenger receptorDSS-induced colitisGut microbial alterationMacrophage polarization

Identifiers

PMID39127850
PMCPMC11316757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.